Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Account Payables (2019 - 2025)

IDEAYA Biosciences' Change in Account Payables history spans 7 years, with the latest figure at -$858000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 128.83% year-over-year to -$858000.0; the TTM value through Dec 2025 reached $2.7 million, down 67.43%, while the annual FY2025 figure was $2.7 million, 67.43% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$858000.0 at IDEAYA Biosciences, down from $1.2 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $9.7 million in Q2 2024 and bottomed at -$3.9 million in Q3 2024.
  • The 5-year median for Change in Account Payables is $387000.0 (2021), against an average of $832100.0.
  • The largest annual shift saw Change in Account Payables skyrocketed 5771.43% in 2022 before it plummeted 3675.0% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at -$7000.0 in 2021, then surged by 5771.43% to $397000.0 in 2022, then soared by 339.55% to $1.7 million in 2023, then surged by 70.54% to $3.0 million in 2024, then crashed by 128.83% to -$858000.0 in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Change in Account Payables are -$858000.0 (Q4 2025), $1.2 million (Q3 2025), and -$364000.0 (Q2 2025).